Nolato AB (publ) (NLTBF)
OTCMKTS · Delayed Price · Currency is USD
6.48
0.00 (0.00%)
Aug 6, 2025, 8:00 PM EDT
Nolato AB Revenue
Nolato AB had revenue of 2.40B SEK in the quarter ending June 30, 2025, a decrease of -1.80%. This brings the company's revenue in the last twelve months to 9.63B, up 1.67% year-over-year. In the year 2024, Nolato AB had annual revenue of 9.66B with 1.24% growth.
Revenue (ttm)
9.63B SEK
Revenue Growth
+1.67%
P/S Ratio
1.60
Revenue / Employee
1.65M SEK
Employees
5,837
Market Cap
1.62B USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.66B | 118.00M | 1.24% |
Dec 31, 2023 | 9.55B | -1.23B | -11.40% |
Dec 31, 2022 | 10.77B | -836.00M | -7.20% |
Dec 31, 2021 | 11.61B | 2.25B | 24.05% |
Dec 31, 2020 | 9.36B | 1.44B | 18.18% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
Nolato AB News
- 6 months ago - Nolato AB (STU:NBF) Q4 2024 Earnings Call Highlights: Strong Profit Growth Amid Sector Challenges - GuruFocus
- 6 months ago - Q4 2024 Nolato AB Earnings Call Transcript - GuruFocus
- 1 year ago - Cyclical Industrials' Turnaround Is Close, Though Nolato Isn't Cheap, It's Still A Buy - Seeking Alpha